Nexalin Technology Granted U.S. Patent #11944806: Transcranial alternating current dynamic frequency stimulation method for anxiety, depression, and insomnia
Portfolio Pulse from Charles Gross
Nexalin Technology, Inc. has been granted U.S. Patent #11944806 for a method of transcranial alternating current dynamic frequency stimulation aimed at treating anxiety, depression, and insomnia. This development could potentially enhance Nexalin's product offerings and market position in the mental health treatment sector.
April 02, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nexalin Technology's new U.S. patent for a mental health treatment method could significantly boost its product line and market standing.
The granting of a U.S. patent for a novel treatment method represents a significant milestone for Nexalin Technology, potentially opening up new markets and enhancing its competitive edge in the mental health treatment industry. This development is likely to be viewed positively by investors, given the growing focus on mental health and the demand for innovative treatment options.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100